藥明生物宣布籌建石家莊生物藥一體化研發(fā)生產(chǎn)中心
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang
(*Please scroll down for English news.)
中國(guó)北京，2018年5月16日
全球領(lǐng)先的生物制藥技術(shù)平臺(tái)公司藥明生物（WuXi Biologics, 2269.HK）宣布，在河北石家莊高新區(qū)籌建世界領(lǐng)先的生物藥一體化研發(fā)生產(chǎn)中心，旨在為全球生物藥開發(fā)、臨床生產(chǎn)及商業(yè)化生產(chǎn)提供一體化解決方案。預(yù)計(jì)項(xiàng)目一期工程將于2020年投產(chǎn)。
項(xiàng)目簽約儀式在北京隆重舉行
藥明生物石家莊生物藥一體化研發(fā)生產(chǎn)中心將由工藝開發(fā)實(shí)驗(yàn)室、產(chǎn)能5,000升的臨床樣品生產(chǎn)基地（藥明生物九廠）和產(chǎn)能48,000升的商業(yè)化生產(chǎn)基地（藥明生物八廠）組成，其設(shè)計(jì)及建設(shè)將符合美國(guó)、歐盟及中國(guó)的cGMP標(biāo)準(zhǔn)。此舉將使藥明生物成為更深、更廣、更寬的生物藥研發(fā)生產(chǎn)賦能平臺(tái)，助力提升石家莊生物制藥產(chǎn)業(yè)的能力和地位，為我國(guó)藥品上市許可持有人制度（MAH）政策提供產(chǎn)能支持，同時(shí)服務(wù)范圍也將輻射全球。
藥明生物全球生產(chǎn)副總裁董健先生代表公司簽約
“我非常高興藥明生物能籌建中國(guó)北方最大的生物藥研發(fā)生產(chǎn)中心，這將有助于我們借力區(qū)域政府支持，吸引更多本地優(yōu)秀人才，賦能當(dāng)?shù)睾献骰锇楦咝У匮邪l(fā)生產(chǎn)生物藥，同時(shí)為全球合作伙伴提供更強(qiáng)大的供應(yīng)鏈網(wǎng)絡(luò)?！彼幟魃锸紫瘓?zhí)行官陳智勝博士表示，“考慮到藥明生物平臺(tái)上研發(fā)的161個(gè)項(xiàng)目未來(lái)可期的生產(chǎn)需求，我們將基于此次投資，快速高效地加強(qiáng)生產(chǎn)業(yè)務(wù)規(guī)模和能力，將藥明生物打造成為全球生物藥商業(yè)化生產(chǎn)服務(wù)領(lǐng)域的領(lǐng)導(dǎo)者。”
關(guān)于藥明生物
藥明生物作為一家香港上市公司，是全球領(lǐng)先的開放式、一體化生物制藥能力和技術(shù)賦能平臺(tái)。公司為全球生物制藥公司和生物技術(shù)公司提供全方位的端到端研發(fā)服務(wù)，幫助任何人、任何公司發(fā)現(xiàn)、開發(fā)及生產(chǎn)生物藥，實(shí)現(xiàn)從概念到商業(yè)化生產(chǎn)的全過(guò)程，加速全球生物藥研發(fā)進(jìn)程，降低研發(fā)成本，造福病患。如需更多信息，請(qǐng)?jiān)L問：www.wuxibiologics.com.cn。
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang
BEIJING, China, May 16, 2018
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.?
The new state-of-the-art biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity which will be built to meet cGMP standards of the United States, the European Union, and China. Besides serving global clients, the new integrated center will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners. Initial phase of the center will be operational in 2020.
“We are very pleased to establish the largest biologics center in northern China, which will enable local companies to more effectively develop and manufacture biologics and in the meantime provide a robust supply chain network for our global clients. This expansion will allow us great access to local talents, markets and government support.” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “With this investment and current 161 biologics programs that WuXi Biologics will manufacture, we will quickly and cost effectively expand our manufacturing capacity to meet our partners’ needs and become one of the global CMO leaders.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
